Navigation Links
published in Medical Technology

VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE

BEDFORD, Mass., July 30 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that scientists reporting in the July 31 issue of SCIENCE have discovered a key disease-related biologic pathway using an integrated and ...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

LONDON, July 7 /PRNewswire/ -- The final analysis of the largest efficacy trial of a cervical cancer vaccine is published today in The Lancet . The study, involving 18,644 women, confirmed GlaxoSmithKline's Cervarix (R) is highly effective at protecting against the two most common cervical cance...

5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH

BRIDGEWATER, N.J., July 6 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) announced today that the results of the long-term, 5-year study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin on progression of retinopathy in patients with type 2 diabetes...

New Review on PROSTVAC(TM) Published by Key Investigators From NCI

KVISTGAARD, Denmark, July 1 /PRNewswire-FirstCall/ -- A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC(TM). This is the most comprehensive and updated Review on PROSTVAC(TM) so...

Clinical and Histopathological Results Using Pollogen's TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy

TEL AVIV, Israel, June 17 /PRNewswire/ -- A recent clinical study using Pollogen's regen(TM) device- the latest aesthetic solution powered by 3rd generation TriPollar(TM) technology, confirms the safety and efficacy of TriPollar(TM) technology in reducing fat and collagen remodeling. The peer ...

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

WASHINGTON, June 7 /PRNewswire/ -- BARI-2D is a useful and focused trial that builds on the body of scientific knowledge physicians use to provide the best possible care for diabetic patients with chronic stable angina and to evaluate their treatment options. The Society for Cardiovascular Angiog...

Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry

- Improvement Was Noted At Day 3 And All Subsequent Study Visits - FORT LEE, N.J., June 3 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today that positive results from a phase 2 clinical trial for lurasidone in the treatment of patients with schizophrenia have been pu...

Clinical Trial Results of Pollogen's TriPollar(TM) Radio Frequency Technology published in the Journal of the European Academy of Dermatology and Venereology

TEL AVIV, Israel, June 2 /PRNewswire/ -- Clinical trial results using the regen(TM) system, the newest aesthetic solution powered by 3rd generation TriPollar RF technology on cellulite treatment and body contouring, have been published in the online Journal of the European Academy of Dermatolo...

Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes

Fertility and Sterility Publishes Article Underscoring Importance of PGD Technique and Method LIVINGSTON, N.J., May 27 /PRNewswire/ -- A group of fertility experts, who pioneered the development of Preimplantation Genetic Screening (PGS), are sharing the step-by-step best practices and expla...

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

Data Confirm Tapentadol Efficacy and Tolerability for Acute Pain Patients RARITAN, N.J., May 26 /PRNewswire-USNewswire/ -- It is estimated that up to 30 percent of all people who have surgery experience gastrointestinal side effects, such as nausea and vomiting. The use of opioid pain medicin...

Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth

- Study provides clinical efficacy of the HairMax LaserComb in the treatment of Androgenetic Alopecia in males commonly known as 'male pattern baldness' - BOCA RATON, Fla., April 20 /PRNewswire/ -- Findings of the pivotal clinical trial of the HairMax LaserComb that provided clear evidence ...

American Lung Association Study to be Published in the 'New England Journal of Medicine' Finds Prescription Heartburn Medication Does Not Control Asthma Symptoms as Previously Thought

--Practice Changing Study Calls on Doctors to Stop Prescribing Potent Heartburn Medications to Asthma Patients Without Frequent Symptoms of Gastric Reflux-- WASHINGTON, April 8 /PRNewswire-USNewswire/ -- For nearly 20 years, it was believed that severe asthma symptoms such as coughing, wheezi...

Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density

INDIANAPOLIS, April 8 /PRNewswire-FirstCall/ -- Phase III data, published online this week in the Journal of Clinical Endocrinology & Metabolism , showed that arzoxifene, an investigational selective estrogen receptor modulator (SERM) being developed by Eli Lilly and Company (NYSE: LLY ), s...

New, Published GELNIQUE Data Show Efficacy, Convenience and Excellent Tolerability

CORONA, Calif., March 16 /PRNewswire-FirstCall/ -- New Phase 3 data, published in the April issue of The Journal of Urology, show that GELNIQUE(TM) (oxybutynin chloride) Gel 10%, the first and only topical gel approved for the treatment of overactive bladder (OAB), is effective at improving th...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well Tolerated When Given With Standard Platelet Therapy KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Results of a Schering-Plough Corporation (NYSE:...

Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology

SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Alternext US: CXM) and its operating unit InnerCool Therapies, Inc., today reported that positive clinical findings demonstrating faster recovery of urinary continence using localized manual cooling techniques during robotic-a...

New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation

DALLAS, March 5 /PRNewswire/ -- A study published by Deborah S. Sarnoff, M.D. et al in the February issue of the Journal of Drugs in Dermatology explores the new generation of carbon dioxide (CO2) laser skin resurfacing technologies, specifically, the SmartXide DOT(TM) laser. DOT utilizes a...

Inverseon's Founder and SAB Member Published in PNAS

SAN FRANCISCO, Feb. 19 /PRNewswire/ -- Inverseon, Inc. ( http://www.inverseon.com ) announces the publication in the February 17, 2009 issue of the Proceedings of the National Academy of Sciences (PNAS) entitled, "Beta2-adrenoceptor signaling is required for the development of an asthma phenotype ...

Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass

Article in Gynecologic Oncology Supports Use of Fujirebio Diagnostics' HE4 Test with CA125 for Risk Stratification of Women with Suspected Ovarian Cancer MALVERN, Pa., Jan. 26 /PRNewswire/ -- A pivotal clinical trial published in the January 2009 issue of the journal Gynecologic Oncology ...

Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults

Synvista Therapeutics Technology Provided CML Biomarker Data for Studies MONTVALE, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. ( NYSE Alternext US: SYI ) today announced two publications demonstrating findings from studies that indicated that the presence of th...

Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet

ROCKVILLE, Md., Dec. 1 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) reports publication in The Lancet , one of the world's leading medical journals, results of clinical trials of its novel circadian regulator, experimental compound tasimelteon (VEC-162). The publication...

Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism

First of Phase 2b studies completes patient screening for enrollment SOUTH SAN FRANCISCO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that the previously reported results of the Phase 2 clinical trial of R788 (fostamatinib disodium),...

Comprehensive Safety Tests Published on Ruyan(R) Smoking Alternatives

Tests Conducted in New Zealand and Canada Find Ruyan E-cigarettes Safe; Results Apply Only to Ruyan Products MINNEAPOLIS, Oct. 28 /PRNewswire/ -- Ruyan America, Inc., announced today the publication of a report that tested the safety of its electronic smoking alternatives, spe...

Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology

- Technology In-Licensed by Stem Cell Sciences From University of Cambridge - ("Stem Cell Sciences", "SCS", "the Company") CAMBRIDGE, England, Oct. 24 /PRNewswire/ -- Stem Cell Sciences plc (AIM: STEM, ASX: STC), a company focused on the commercialisation of stem cells and stem cell ...

Diamyd(R) Study Published in Prestigious New England Journal of Medicine

STOCKHOLM, October 9 /PRNewswire-FirstCall/ -- Diamyd Medical reports that the world's most influential medical journal, the New England Journal of Medicine, has published an article with results from the company's study of the Diamyd(R) diabetes vaccine for type 1 diabetes. (Logo: http://w...

Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD

In a clinical study of adults, VYVANSE taken once-daily significantly improved the symptoms of ADHD within one week PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published in th...

Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet

PRINCETON, N.J., Sept. 25 /PRNewswire/ -- Data from a 52-week phase 3 study (LEADTM 3) of Novo Nordisk's (NYSE: NVO ) liraglutide, a once-daily human GLP-1 analog, were published online today in The Lancet. The study showed that liraglutide, when taken alone, produces statistically significan...

First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease

QIAGEN's careHPV test provides 'substantially more accurate' front-line screening VENLO, Netherlands, Sept. 21 /PRNewswire-FirstCall/ -- A new HPV test developed by QIAGEN specifically for use in regions of the world with scarce resources is "substantially" more a...

Interleukin Genetics Wins International Award for Outstanding Research Published in the Journal, Nutrition

Paper Reports Value of Specific Nutritional Products is Dependent on Individual's Genetic Make-up WALTHAM, Mass., Sept. 12 /PRNewswire-FirstCall/ -- Researchers at Interleukin Genetics, Inc. (Amex: ILI ), today received the 12th John M. Kinney Award for Nutrition and Me...

The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC

Summary: Protein Tomography(TM) has yet Again Provided Structural Proof of a Drug Target Function. A Study Performed by Sidec and UCB, Characterizes the Target of Anti-Epileptic Drug in Situ Where Two Major Conformations Have Been Identified STOCKHOLM, September 9 /P...

TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet

Landmark ARB trial investigated Micardis(R) (telmisartan) against placebo in reducing the composite endpoint of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure in ACE inhibitor intolerant high-risk patients receiving current standard of ca...

Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE

BETHESDA, Md., Aug. 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, will host a webcast and conference call this morning, Monday, August 18, 200...

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

First T cell engaging antibody (BiTE) showing clinical benefit in cancer patients; Blinatumomab enables patients own T cells to recognize and attack cancer cells BETHESDA, Md., Aug. 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical c...

CryoCath Arctic Front(R) Results Published in JACC

- Strong efficacy results from a multi-center 293-patient European trial - http://www.cryocath.com Toronto Stock Exchange Symbol: CYT MONTREAL, July 22 /PRNewswire-FirstCall/ - CryoCath(R) Technologies Inc., the global leader in cryotherapy products to treat cardiac arrhythmias, toda...

Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes

Two Regimens Including Lantus(R) and Apidra(R) Resulted in Significant Reductions in A1C in Patients with Type 2 Diabetes, Whatever the Algorithm Used BRIDGEWATER, N.J., July 22 /PRNewswire/ -- Results from the "Adjust to Target in Type 2 Diabetes: Comparison...

Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology

SAN DIEGO, July 21 /PRNewswire/ -- Bioimpedance spectroscopy (BIS) is more accurate and reliable than other methods of subclinical assessment of lymphedema in breast cancer patients, according to a paper published in the July 20 issue of Journal of Clinical Oncology (2008; Vol. 26, Issue 21: 3...

Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology

Results are basis for CTI's Marketing Authorization Application currently under review by the EMEA SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTA) today announced the publication of results from its randomized phase III trial ...

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

HOUSTON, July 1 /PRNewswire/ -- Agennix Incorporated today announced the publication of final results from a Phase 2 monotherapy trial with talactoferrin alfa in patients who had failed previous treatment for advanced or metastatic renal cell carcinoma (RCC). Results from the study, which were...

Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease

SOUTH SAN FRANCISCO, Calif. and ALLSCHWIL, Switzerland, June 20 /PRNewswire/ -- Actelion Ltd (SWX: ATLN) announced today that data published in The Lancet(1) show that, in mildly symptomatic pulmonary arterial hypertension (PAH) patients (WHO functional class II - WHO FC II), bosentan (Traclee...

Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma

CAMBRIDGE, Mass., June 10 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR ) today announced that the results from its Phase III orthopedic trial (HEM-115) have been published in the June 2008 issue of the Journal of Trauma. This paper is entitled "HBOC-201 as an Alternative to Blo...
Other Tags
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
(Date:10/14/2014)... N.C. – Like discriminating thieves, prostate cancer tumors scavenge ... the body. But such avarice may be a fatal ... a way to kill prostate cancer cells by delivering ... selectively destroys the diseased cells brimming with the mineral, ... uses two drugs already commercially available for other uses, ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
(Date:10/20/2014)... MA (PRWEB) October 20, 2014 ... sponsoring a booth at the American Foundation for Suicide ... 25th. The AFSP is a not-for-profit organization that hosts ... Net proceeds from these events are used to help ... but education and personal relationships as well. , ...
(Date:10/20/2014)... October 20, 2014 hc1.com today ... secure cloud solution that enables healthcare organizations of ... ultimate healthcare-specific customer relationship management (“CRM”) solution. , ... unique needs of the healthcare industry, the hc1 ... providers and patients by combining healthcare CRM, HIPAA-compliant ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Unveiled at ... new Strategic Direction Scorecard conservatively estimates member hospital ROI on ... spent on dues, The Center provides $12.50 in value to ... is (Member Value – Member Dues)/Member Dues. , “This ... at this number and we think the methodology is really ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
Other Contents